Search details
1.
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
Oncologist
; 22(1): 41-52, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27807302
2.
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
Value Health
; 20(7): 866-875, 2017.
Article
in English
| MEDLINE | ID: mdl-28712615
3.
Circulating tumor cells in prostate cancer: beyond enumeration.
Clin Adv Hematol Oncol
; 15(1): 63-73, 2017 Jan.
Article
in English
| MEDLINE | ID: mdl-28212371
4.
Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?
Clin Adv Hematol Oncol
; 14(11): 907-914, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27930642
5.
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Cancer
; 121(18): 3298-306, 2015 Sep 15.
Article
in English
| MEDLINE | ID: mdl-26033830
6.
Literature Review and Profile of Cancer Diseases Among Afghan Refugees in Iran: Referrals in Six Years of Displacement.
Med Sci Monit
; 21: 3622-8, 2015 Nov 23.
Article
in English
| MEDLINE | ID: mdl-26592372
7.
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cancer
; 120(12): 1871-80, 2014 Jun 15.
Article
in English
| MEDLINE | ID: mdl-24634003
8.
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Invest New Drugs
; 32(1): 178-87, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24242861
9.
Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Clin Adv Hematol Oncol
; 12(2): 90-9, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24892254
10.
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Int J Cancer
; 133(4): 788-96, 2013 Aug 15.
Article
in English
| MEDLINE | ID: mdl-23319457
11.
Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium.
Clin Adv Hematol Oncol
; 16(6): 423-425, 2018 06.
Article
in English
| MEDLINE | ID: mdl-30067613
12.
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary.
Clin Adv Hematol Oncol
; 16 Suppl 1(1): 21-23, 2018 Jan.
Article
in English
| MEDLINE | ID: mdl-29742094
13.
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Lancet Oncol
; 13(8): 827-37, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22759480
14.
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
J Clin Oncol
; 41(11): 1965-1971, 2023 04 10.
Article
in English
| MEDLINE | ID: mdl-37018919
15.
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Cancer
; 118(24): 6055-62, 2012 Dec 15.
Article
in English
| MEDLINE | ID: mdl-22674198
16.
STAT3: a target to enhance antitumor immune response.
Curr Top Microbiol Immunol
; 344: 41-59, 2011.
Article
in English
| MEDLINE | ID: mdl-20517723
17.
Systemic therapy in renal cell carcinoma: advancing paradigms.
Oncology (Williston Park)
; 26(3): 290-301, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-22545314
18.
Advance Care Planning in Patients With Metastatic Cancer: A Quality Improvement Initiative.
JCO Oncol Pract
; 18(10): e1562-e1566, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35849788
19.
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Urol Oncol
; 40(11): 495.e1-495.e10, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35973929
20.
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
BJU Int
; 108(5): 665-72, 2011 Sep.
Article
in English
| MEDLINE | ID: mdl-21265994